After American drugmaker Moderna, German pharmaceutical company BioNotech and its partner US pharmaceutical company Pfizer have sought approval to use the Corona vaccine.
BioNotech and its partner US pharmaceutical company Pfizer said on Tuesday that they had submitted an application to the European Medicines Agency for approval of their vaccine for corona virus. The two companies said the review process for the applications submitted on Monday was completed. He started it before the agency on 6 October.
US pharmaceutical company Moderna has requested US and European regulators to allow emergency use of their Covid-19 vaccine. Moderna, a frontrunner in developing the Corona vaccine, claimed that her vaccine had been effective in all types of classes and groups. The company said that the vaccine was 94.1 percent effective after the third phase of the trial. More than 30,000 people have participated in the trial of Moderna’s vaccine. The company claimed that its vaccine was 100% effective in preventing patients from reaching critical condition.
The move comes a day after this request from rival company Moderna. BioNotech has stated that the vaccine is currently named ‘BNT162B2’ and if it is approved, use in Europe could begin before the end of 2020.
The World Health Organization (WHO) chief said that Mexico is in a bad state due to the Kovid-19 epidemic. Simultaneously, the WHO urged Mexico’s leaders to take a serious view of the transition and set an example for their citizens. WHO Director General T. A. Gabres’s statement came on Monday, when the death toll from the epidemic in Mexico rose to 1,05,940. So far, 1,113,543 cases of infection have been reported in the country. The actual number of infected in Mexico is estimated to be much higher due to the decrease in the number of investigations.
Gabresas said that the increasing cases of infection in Mexico are worrisome. President Lopez Obrador has been criticized several times for not applying the mask. The WHO chief urged the country’s leaders to take a serious approach towards the epidemic.